Pharsight

Drugs that contain Loteprednol Etabonate

1. Eysuvis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11872318 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US11642317 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US11596599 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 26, 2023

Market Authorisation Date: 26 October, 2020

Treatment: A method for treating dry eye in a patient

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

EYSUVIS family patents

Family Patents

2. Eysuvis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219596 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10857096 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10945948 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10940108 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US10993908 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US10646436 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 26, 2023

Market Authorisation Date: 26 October, 2020

Treatment: A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the ey...

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

EYSUVIS family patents

Family Patents

3. Inveltys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11872318 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US11642317 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

Market Authorisation Date: 22 August, 2018

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

INVELTYS family patents

Family Patents

4. Inveltys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US11219597 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10864219 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US10646437 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

Market Authorisation Date: 22 August, 2018

Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method of reducing post-surgical pain following ocular surgery; A ...

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

INVELTYS family patents

Family Patents

5. Lotemax Sm patents expiration

LOTEMAX SM's oppositions filed in EPO
LOTEMAX SM Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11534395 BAUSCH AND LOMB INC Ophthalmic suspension composition
Jan, 2036

(11 years from now)

US10596107 BAUSCH AND LOMB INC Ophthalmic suspension composition
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength (NS) Feb 22, 2022

Market Authorisation Date: 22 February, 2019

Treatment: Treatment of post-operative inflammation and pain following ocular surgery

Dosage: GEL;OPHTHALMIC

How can I launch a generic of LOTEMAX SM before it's drug patent expiration?
More Information on Dosage

LOTEMAX SM family patents

Family Patents